North America

Envetec has named Patrick S. Jones, president of Thermo Fisher's Clinical Diagnostics Division, as an independent director to support its US expansion.

California's public health regulator has approved the Irish cleantech firm's non-thermal GENERATIONS system for biohazardous and sharps waste treatment.

The Florida biotech has secured a USPTO notice of allowance covering HCW9302 as an alopecia areata treatment, as Phase 1 data show early signs of

Lumexa Imaging swung to a $2.7m net profit in Q2 2026 as advanced imaging volumes grew 6.8% and the company added its ninth

NorthStrive Biosciences has formalised a six-month expansion programme to narrow four AI-discovered mitochondrial compounds toward a lead nomination in cardiac disease

A late-stage development advance in Centessa's OX2R agonist pipeline triggers an $8.6 million payment to Nxera, which retains future milestone and royalty

The USPTO notice covers LSD1 inhibitor combinations for myeloid cancers, with protection expected to run to 2042 pending formal grant.

Philips has introduced a transvaginal transducer claiming a 41.7% penetration gain and 22% weight reduction over its predecessor, with dual regulatory clearance.

NorthStrive Biosciences will test probiotic candidates EL-22 and EL-32 in a live-mouse microgravity study under a non-binding deal with Australia's

Vivos Inc. has validated its PrecisionGel polymer platform in an Elsevier journal, supporting clinical programmes at Mayo Clinic and licensing talks with pharmaceutical

BioStem Technologies has secured GPO contract coverage for VENDAJE and VENDAJE AC through Vizient and Premier, opening hospital access for the first time.

The CRISPR biotech drew an initial $75m at closing, with further tranches tied to milestones for its HAE gene-editing candidate lonvo-z.

Kala Bio will be the sole US distributor of Virotek's ophthalmology genomic testing programme under a one-year deal effective 4 September 2026.

The HORIZON Phase 3 trial of pelacarsen failed its primary cardiovascular endpoint, but royalty backer Royalty Pharma says it still expects a modest positive return.

Tarsus gains worldwide rights to Phase 3 oral candidate ALK-001 for Stargardt disease, a blinding inherited retinal condition with no approved therapy.

The Paris-based robotics firm said blue-chip automotive, logistics and healthcare operators are among early adopters of its Calvin-40 humanoid robot.

Palopegteriparatide gains a positive reimbursement recommendation in Canada for adults with chronic hypoparathyroidism inadequately controlled on standard therapy.

Phase 1 data show CLYM116 achieved near-complete APRIL suppression and a 29-day half-life, supporting quarterly dosing in IgA nephropathy.

Eledon Pharmaceuticals has submitted an IND for a registrational islet cell transplant study of tegoprubart, while reaffirming its Q4 2026 Phase 3 kidney trial start.

The Thousand Oaks biotech floated on Nasdaq in August 2026 and published NEJM data on its lead NaV 1.8 inhibitor onzotrigine in acute pain.